

## Re: Your request made under the Freedom of Information Act 2000

Please answer the questions with regards to NHS patients, i.e., excluding patients that receive treatment as part of clinical trials or private healthcare.

### Patients with acute myeloid leukaemia (AML)

- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

1. How many patients have received treatment with venetoclax for AML during the past 24 months? **Note:** please provide data for the most recent 24-month period available via your prescribing/management system.

Answer:

2. What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?

Answer:

3. What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle)

Answer:

4. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?

Answer:

### Patients with chronic lymphocytic leukaemia (CLL)

- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

5. Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.

**Note:** please provide data for the most recent 24-month period available via your prescribing/management system.

	Treatment regimens		
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this			

Our Ref: 74/2023  
JANUARY 2023

treatment regimen during the past 24 months			
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*			
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months			

\*We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.

**Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)**

- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**
6. Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs<sup>†</sup> used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months				

**†Note:** There are five different pack sizes of venetoclax available in the UK:

- Pack 1: venetoclax 10 mg x 14 tablets
- Pack 2: venetoclax 50 mg x 7 tablets
- Pack 3: venetoclax 100 mg x 7 tablets
- Pack 4: venetoclax 100 mg x 14 tablets
- Pack 5: venetoclax 100 mg x 112 tablets

7. Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?

Answer:

Our Ref: 74/2023  
JANUARY 2023